MedTrace Logo

Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder

NCT03066700 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2019-02-28

No results posted yet for this study

Summary

This is a retrospective study to identify the prognostic factors of the good outcomes in patients who presented with upper GI bleeding from tumor and received Hemospray via endoscopy for hemostatic control. The good outcomes were assessed by immediate hemostasis, rebleeding at 72 hours as well as 7, 14 and 30 days following presentation at initial bleeding episode and also 6-month survival rate.

Conditions

  • Death

Interventions

DEVICE

Hemostatic powder

HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.

Sponsors & Collaborators

  • McGill University

    collaborator OTHER

  • King Chulalongkorn Memorial Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-06-01
Completion
2017-08-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03066700 on ClinicalTrials.gov